# Clinical Study Comparing Single Long BioMimeTM Morph Coronary Stent System vs. Two Overlapping Xience Family Coronary Stent Systems in the Treatment of Patients With Long de Novo Lesions.

Study · id `cardio:ct-nct03721614` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03721614](<https://clinicaltrials.gov/study/NCT03721614>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03721614

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT03721614. Randomized; no masking; primary purpose treatment. Start 2019-09-15 (anticipated); primary completion 2021-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT03721614, source copy `cardio:ctgov-nct03721614-2019-08-14`, retrieved 2026-10-26)
- Planned start: 2019-09-15 (anticipated) (ClinicalTrials.gov record NCT03721614, source copy `cardio:ctgov-nct03721614-2019-08-14`, retrieved 2026-10-26)
- Primary completion: 2021-12-01 (anticipated) (ClinicalTrials.gov record NCT03721614, source copy `cardio:ctgov-nct03721614-2019-08-14`, retrieved 2026-10-26)
- Completion: 2022-06-22 (anticipated) (ClinicalTrials.gov record NCT03721614, source copy `cardio:ctgov-nct03721614-2019-08-14`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03721614-2019-08-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Study Comparing Single Long BioMimeTM Morph Coronary Stent System vs. Two Overlapping Xience Family Coronary Stent Systems in the Treatment of Patients With Long de Novo Lesions.
- Acronym: Morph RCT-1
- Condition: Coronary Artery Disease
- Intervention (Device): BioMime™ Morph - Sirolimus Eluting Coronary Stent System
- Intervention (Device): Xience family Everolimus Coronary Stent Systems
- Lead sponsor: Meril Life Sciences Pvt. Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Meril Life Sciences Pvt. Ltd. (`cardio:org-meril-life-sciences-pvt-ltd`)

## Provenance

Content hash: a1cc186eab21c29dbf27dd592e6df5a4fb426d518d7c22837f5c2a731a48ae61
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
